Skip to content
Search

Latest Stories

Pharmacist wins £58,000 compensation in racial harassment case against Boots

Pharmacist wins £58,000 compensation in racial harassment case against Boots

An Employment Tribunal upheld 7 claims of harassment related to race brought by the pharmacist against Boots and one of its pharmacy technicians

A tribunal has ordered Boots to pay over £58,000 in compensation and costs to a pharmacist who was racially profiled at work.

S.Famojuro, a black pharmacist of Nigerian national origin, experienced racial harassment from pharmacy team members during a shift on 18 July 2020.


The Pharmacists’ Defence Association (PDA), the independent trade union for pharmacists, represented the pharmacist throughout the internal grievance processes and at the Employment Tribunal hearing.

In a detailed written judgment, the pharmacy team members and company managers were heavily criticised by the Tribunal, after finding that a pre-registration pharmacy technician and a pharmacy advisor had undermined Famojuro in his professional role as the Responsible Pharmacist (RP) and insulted him.

The pharmacist lodged a grievance with Boots regarding his treatment, but it took the company over four months to initiate the investigation and set a meeting date, and this was only done after the PDA intervened to address the unacceptable delays.

However, the Judge described the grievance investigation conducted by an experienced store manager as “simply not fit for purpose” and lacking a “basic level of competence.”

The grievance manager was found to be inadequately trained for conducting grievances into serious allegations of discrimination, and there were unacceptable delays in dealing with the complaints.

The Tribunal concluded that Boots' actions had seriously damaged the relationship of mutual trust and confidence, leading to Famojuro's resignation, which was determined to be a case of constructive unfair dismissal.

The grievance outcome was issued on 15 January 2021, with all of the pharmacist's complaints being dismissed, except for one regarding delays in the investigation.

Unsatisfied, the pharmacist appealed against the outcome, leading to the appointment of an area manager to hear the appeal.

However, the appeal manager did nothing to probe further the conduct of the pharmacy technician and pharmacy advisor, with the Tribunal noting that his inquiry was "superficial and lacked insight."

After receiving the appeal outcome, the pharmacist resigned with a notice on 3 April 2021. The apology arrived on 12 May 2021, almost 6 weeks after his resignation.

The Tribunal described this as “the classic formulation of a non-apology” noting that it “must have rubbed salt in the Claimant’s wounds”.

Following a 5-day hearing earlier this year, the Tribunal upheld 7 claims of harassment related to race brought by the pharmacist against Boots and the pharmacy technician, as well as his claim of constructive unfair dismissal.

In a remedy hearing, the Tribunal awarded Famojuro £45,263.11 for loss of earnings, injury to feelings, aggravated damages, an uplift for failure to follow the ACAS Code, and interest. Additionally, costs of £13,357.25 were awarded to the PDA, bringing the total compensation and costs to £58,620.36.

Mark Pitt, General Secretary of the PDA Union said: “Rather than properly investigate Mr Famojuro’s complaints and condemn the racist behaviour of their employees at the time of the incident, the company supported them throughout, denying any racism had occurred.

“Consequently, Mr Famojuro was put through 4 years of stress and court proceedings to secure justice for his discriminatory treatment.

“The PDA legal team have been behind him all the way and the high award and aggravated damages reflect the extreme displeasure of the employment tribunal panel at the conduct of company and its witnesses, some of whom were found to have lied and fabricated evidence. “

Wai Chan, Vice President of the PDA BAME Pharmacists Network which leads anti-racist activity for the PDA, stated that they will review this case to inform their future activity.”

The PDA emphasised that unlawful discrimination related to race is unacceptable, and urges members who encounter discrimination at work to seek advice from the PDA Member Support Centre.

More For You

Mike Hewitson, superintendent pharmacist & managing director of Beaminster Pharmacy

Mike Hewitson elected as NPA board member for England

Mike Hewitson elected as NPA board member for England: New term begins April

Mike Hewitson, superintendent pharmacist & managing director ofBeaminster Pharmacy, has been elected as the next National Pharmacy Association (NPA) board member for England.

Since 2023, Hewitson has served as chair of Community Pharmacy Dorset. He is also a member of Somerset Council and a Non-Executive Director at HubRx.

Keep ReadingShow less
Store closures 2024: Chemists among hardest hit

Over 600 chemist shops belonging to multiples and chains were closed last year

Getty Images

35 shops closed per day last year, chemists worst affected

More shops are expected to exit the UK high streets driven by driven by rising operational costs and a continued shift towards online shopping and transactions.

According to figures from PwC, a total of 12,804 outlets operated by chains (those with five or more locations) exited high streets, shopping centres and retail parks in 2024 – equivalent to 35 closures per day.

Keep ReadingShow less
Empty pharmacy shelves due to UK medicine shortages.

The government has said it's investing up to £520m to manufacture more medicines

Pic credit: iStock

Brexit blamed for UK medicine shortages with "little sign of recovery"

The UK is facing “a worsening situation” with drugs shortages compared to the rest of Europe as a result of Brexit, according to the Nuffield Trust health thinktank.

It comes of the back of data that revealed that the department of health and social care (DHSC) received 1,938 notifications of disruptions to medicine supply last year – the highest in four years.

Keep ReadingShow less
Alert! Patients on Promixin should be switched to alternatives by 30 April

Promixin is licensed for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in adults and children with cystic fibrosis

Getty Images

Medicine shortage: Promixin to be discontinued from May 2025

The Department of Health and Social Care (DHSC) and NHS England have issued a national patient safety alert regarding the upcoming shortage of Promixin (colistimethate).

The alert, issued on 17 March 2025, states that Promixin (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025, with stocks expected to be exhausted by this time.

Keep ReadingShow less
PAGB welcomes new vice-presidents and treasurer to Board

Rob Elliott and Bas Vorsteveld ( L-R)

Bas Vorsteveld will now oversee the Kenvue’s business in Northern Europe

PAGB appoints new vice-presidents and treasurer to Board

PAGB, the consumer healthcare association, has announced the appointment of two new vice-presidents and a treasurer to their Board.

Bas Vorsteveld, area managing director for Northern Europe at Kenvue, and Rob Elliott, OTC centre of excellence lead at Viatris, have been elected as vice-presidents.

Keep ReadingShow less